Browse our 650+ Publications​

Latest Publications

Insertional activation of STAT3 and LCK by HIV-1 proviruses in T cell lymphomas

Mellors JW, et al.
November 2021
Authors and Affiliates
John W Mellors 1, Shuang Guo 2, Asma Naqvi 1, Leah D Brandt 1, Ling Su 2, Zhonghe Sun 2, Kevin W Joseph 1, Dimiter Demirov 2, Elias K Halvas 1, Donna Butcher 2, Beth Scott 3, Aaron Hamilton 3, Marintha Heil 3, Baktiar Karim 2, Xiaolin Wu 2, Stephen H Hughes 4; 1 Department of Medicine, University of Pittsburgh, Pittsburgh, PA, USA. 2 Leidos Biomedical Research, Inc., Frederick National Laboratory for Cancer Research, Frederick, MD, USA. 3 Roche Molecular Diagnostics, Pleasanton, CA, USA. 4 HIV Dynamics and Replication Program, CCR, National Cancer Institute, Frederick, MD, USA.

Identification of conserved SARS-CoV-2 spike epitopes that expand public cTfh clonotypes in mild COVID-19 patients

Lu X, et al.
November 2021
Authors and Affiliates
Xiuyuan Lu 1, Yuki Hosono 1,2,3, Masamichi Nagae 1,2, Shigenari Ishizuka 1,2, Eri Ishikawa 1,2, Daisuke Motooka 4, Yuki Ozaki 4, Nicolas Sax 5, Yuichi Maeda 3,6, Yasuhiro Kato 3,7, Takayoshi Morita 3,7, Ryo Shinnakasu 8, Takeshi Inoue 8, Taishi Onodera 9, Takayuki Matsumura 9, Masaharu Shinkai 10, Takashi Sato 10, Shota Nakamura 4, Shunsuke Mori 11,12, Teru Kanda 13, Emi E Nakayama 14, Tatsuo Shioda 14,15, Tomohiro Kurosaki 8,15,16, Kiyoshi Takeda 6,15,17, Atsushi Kumanogoh 3,7,15, Hisashi Arase 11,12,15, Hironori Nakagami 18, Kazuo Yamashita 5, Yoshimasa Takahashi 9, Sho Yamasaki 1,2,15,19,20; 1 Laboratory of Molecular Immunology, Immunology Frontier Research Center, Osaka University, Suita, Japan. 2 Department of Molecular Immunology, Research Institute for Microbial Diseases, Osaka University, Suita, Japan. 3 Department of Respiratory Medicine and Clinical Immunology, Graduate School of Medicine, Osaka University, Suita, Japan. 4 Department of Infection Metagenomics, Genome Information Research Center, Research Institute for Microbial Diseases, Osaka University, Suita, Japan. 5 KOTAI Biotechnologies, Inc., Suita, Japan. 6 Laboratory of Immune Regulation, Department of Microbiology and Immunology, Graduate School of Medicine, Osaka University, Suita, Japan. 7 Department of Immunopathology, Immunology Frontier Research Center, Osaka University, Suita, Japan. 8 Laboratory of Lymphocyte Differentiation, Immunology Frontier Research Center, Osaka University, Suita, Japan. 9 Research Center for Drug and Vaccine Development, National Institute of Infectious Diseases, Tokyo, Japan. 10 Tokyo Shinagawa Hospital, Tokyo, Japan. 11 Department of Immunochemistry, Research Institute for Microbial Diseases, Osaka University, Suita, Japan. 12 Laboratory of Immunochemistry, Immunology Frontier Research Center, Osaka University, Suita, Japan. 13 Division of Microbiology, Faculty of Medicine, Tohoku Medical and Pharmaceutical University, Sendai, Japan. 14 Department of Viral Infections, Research Institute for Microbial Diseases, Osaka University, Suita, Japan. 15 Center for Infectious Disease Education and Research, Osaka University, Suita, Japan. 16 Laboratory of Lymphocyte Differentiation, RIKEN Center for Integrative Medical Sciences, Yokohama, Japan. 17 Department of Mucosal Immunology, Immunology Frontier Research Center, Osaka University, Suita, Japan. 18 Department of Health Development and Medicine, Graduate School of Medicine, Osaka University, Suita, Japan. 19 Division of Molecular Immunology, Medical Mycology Research Center, Chiba University, Chiba, Japan. 20 Division of Molecular Design, Research Center for Systems Immunology, Medical Institute of Bioregulation, Kyushu University, Fukuoka, Japan.

Distinct tumor-infiltrating lymphocyte landscapes are associated with clinical outcomes in localized non-small cell lung cancer

Federico L, et al.
November 2021
Authors and Affiliates
L Federico 1, D J McGrail 2, S-E Bentebibel 3, C Haymaker 4, A Ravelli 3, M-A Forget 3, T Karpinets 5, P Jiang 6, A Reuben 6, M V Negrao 6, J Li 5, R Khairullah 6, J Zhang 5, A Weissferdt 7, A A Vaporciyan 8, M B Antonoff 8, G Walsh 8, S-Y Lin 2, A Futreal 5, I Wistuba 4, J Roth 8, L A Byers 6, P-O Gaudreau 9, N Uraoka 4, A F Cruz 4, H Dejima 4, R N Lazcano 4, L M Solis 4, E R Parra 4, J J Lee 10, S Swisher 8, T Cascone 6, J V Heymach 6, J Zhang 11, B Sepesi 12, D L Gibbons 13, C Bernatchez 14; 1 Therapeutics Discovery Division. 2 Department of Systems Biology. 3 Department of Melanoma Medical Oncology. 4 Department of Translational Molecular Pathology. 5 Department of Genomic Medicine. 6 Department of Thoracic and Head & Neck Medical Oncology. 7 Department of Pathology. 8 Department of Thoracic and Cardiovascular Surgery, The University of Texas MD Anderson Cancer Center; Houston, Texas, 77030, USA. 9 Department of Oncology, Queens' University and the Canadian Cancer Trials Group; Kingston, Ontario, Canada. 10 Department of Biostatistics. 11 Department of Genomic Medicine; Department of Thoracic and Head & Neck Medical Oncology. Electronic address: jzhang20@mdanderson.org. 12 Department of Thoracic and Cardiovascular Surgery, The University of Texas MD Anderson Cancer Center; Houston, Texas, 77030, USA. Electronic address: bsepesi@mdanderson.org. 13 Department of Thoracic and Head & Neck Medical Oncology; Department of Molecular and Cellular Oncology, The University of Texas MD Anderson Cancer Center; Houston, Texas, 77030, USA. Electronic address: dlgibbon@mdanderson.org. 14 Department of Melanoma Medical Oncology. Electronic address: cbernatchez@mdanderson.org.

A Phase I, Open-Label, Dose-Escalation Study of the OX40 Agonist Ivuxolimab in Patients With Locally Advanced or Metastatic Cancers

Diad A, et al.
November 2021
Authors and Affiliates
Adi Diab 1, Omid Hamid 2, John A Thompson 3, Willeke Ros 4, Ferry A L M Eskens 5, Toshihiko Doi 6, Siwen Hu-Lieskovan 7, Samuel J Klempner 8, Bishu Ganguly 9, Catherine Fleener 10, Xiao Wang 11, Tenshang Jo 11, Ken Liao 12, Shahram Salek-Ardakani 13, Carrie Turich Taylor 9, Jeffrey Chou 14, Anthony B El-Khoueiry 15; 1 Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center adiab@mdanderson.org. 2 Research, The Angeles Clinic and Research Institute, A Cedars-Sinai Affiliate. 3 Medicine/Medical Oncology, University of Washington. 4 Netherlands Cancer Institute. 5 Department of Medical Oncology, Erasmus MC Cancer Institute. 6 Department of Experimental Therapeutics, National Cancer Center Hospital East. 7 David Geffen School of Medicine at UCLA. 8 Oncology, Massachusetts General Hospital. 9 Pfizer Inc. 10 Translational Medicine, Xencor Inc. 11 Pfizer (United States). 12 Clinical Pharmacology, Pfizer (United States). 13 Cancer Immunology Discovery, Pfizer (United States). 14 WRDM, Pfizer (United States). 15 Division of Medical Oncology, USC Norris Comprehensive Cancer Center.

An allogeneic multiple myeloma GM-CSF-secreting vaccine with lenalidomide induces long-term immunity and durable clinical responses in patients in near complete remission

Biavat L, et al.
November 2021
Authors and Affiliates
Luca Biavati 1, Carol Ann Huff 2, Anna Ferguson 3, Amy Sidorski 4, M Amanda Stevens 5, Lakshmi Rudraraju 6, Cristina Zucchinetti 1, Syed Abbas Ali 2, Philip Imus 1, Christian B Gocke 2, Rachel M Gittelman 7, Sarah Johnson 8, Catherine Sanders 9, Marissa Vignali 10, Anita Gandhi 11, Xiaobu Ye 3, Kimberly A Noonan 6, Ivan Borrello 12; 1 Oncology, Johns Hopkins Medicine. 2 Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine. 3 Oncology, Johns Hopkins University. 4 Johns Hopkins University School of Medicine. 5 Hematologic Malignancies, Johns Hopkins Medicine. 6 Johns Hopkins Medicine. 7 Adaptive Biotechnologies (United States). 8 Computational Biology, Adaptive Biotechnologies (United States). 9 Business Development, Adaptive Biotechnologies (United States). 10 Adaptive Biotechnology. 11 Bristol-Myers Squibb (United States). 12 Oncology, Johns Hopkins University School of Medicine iborrell@jhmi.edu.

T cell receptor repertoires as potential diagnostic markers for patients with COVID-19

Hou X, et al.
November 2021
Authors and Affiliates
Xianliang Hou 1, Wentao Fan 2, Guangyu Wang 3, Xiaoyan Chen 4, Chune Mo 1, Yongsi Wang 2, Weiwei Gong 1, Xuyan Wen 5, Hui Chen 2, Dan He 2, Lijun Mo 6, Shaofeng Jiang 7, Minglin Ou 8, Haonan Guo 9, Hongbo Liu 10; 1 Central Laboratory, Guangxi Health Commission Key Laboratory of Glucose and Lipid Metabolism Disorders, the Second Affiliated Hospital of Guilin Medical University, Guilin, 541199, China. 2 Guangzhou Huayin Health Medical Group Co., Ltd (Guangzhou, China). 3 College of Laboratory Medicine, Guilin Medical University, Guilin, 541199, China. 4 Department of State owned Assets Management, Affiliated Hospital of Guilin Medical University, Guilin, 541001, China. 5 Department of pathology, Affiliated Hospital of Guilin Medical University, Guilin, 541001. 6 Clinical Laboratory, the Second Affiliated Hospital of Guilin Medical University, Guilin, 541199. 7 Guangxi Key Laboratory of Tumor Immunology and Microenvironmental Regulation, Guilin Medical University, Guilin, Guangxi, 541199, China. 8 Central Laboratory, Guangxi Health Commission Key Laboratory of Glucose and Lipid Metabolism Disorders, the Second Affiliated Hospital of Guilin Medical University, Guilin, 541199, China. Electronic address: minglinou@glmc.edu.cn. 9 Department of Clinical Laboratory, The Affiliated Hospital of Guilin Medical University, Guilin, Guangxi, 541001, China. Electronic address: guohaonan@glmc.edu.cn. 10 Department of Laboratory Medicine, the Second Affiliated Hospital of Guilin Medical University, Guilin, 541199, China. Electronic address: hbliu@glmc.edu.cn.

K 2P 18.1 translates T cell receptor signals into thymic regulatory T cell development

Ruck T, et al.
November 2021
Authors and Affiliates
Tobias Ruck #,1,2, Stefanie Bock #,3, Steffen Pfeuffer 4, Christina B Schroeter 4, Derya Cengiz 4,3, Paul Marciniak 4,3, Maren Lindner 3, Alexander Herrmann 4, Marie Liebmann 3, Stjepana Kovac 3, Lukas Gola 3, Leoni Rolfes 4, Marc Pawlitzki 4 3, Nils Opel 5, Tim Hahn 5, Udo Dannlowski 5, Thomas Pap 6, Felix Luessi 7, Julian A Schreiber 8,9, Bernhard Wünsch 8, Tanja Kuhlmann 10, Guiscard Seebohm 9, Björn Tackenberg 11, Patricia Seja 12, Frank Döring 13, Erhard Wischmeyer 13, Achmet Imam Chasan 14, Johannes Roth 14, Luisa Klotz 3, Gerd Meyer Zu Hörste 3, Heinz Wiendl 3, Tobias Marschall 15, Stefan Floess 16, Jochen Huehn 16, Thomas Budde 17, Tobias Bopp 18, Stefan Bittner 7, Sven G Meuth 4,3; 1 Department of Neurology, Medical Faculty, Heinrich-Heine-University, Düsseldorf, Germany. tobias.ruck@med.uni-duesseldorf.de. 2 Department of Neurology with Institute of Translational Neurology, University of Münster, Münster, Germany. tobias.ruck@med.uni-duesseldorf.de. 3 Department of Neurology with Institute of Translational Neurology, University of Münster, Münster, Germany. 4 Department of Neurology, Medical Faculty, Heinrich-Heine-University, Düsseldorf, Germany. 5 Institute for Translational Psychiatry, University of Münster, Münster, Germany. 6 Institute of Experimental Musculoskeletal Medicine (IMM), University of Münster, Münster, Germany. 7 Department of Neurology, Focus Program Translational Neuroscience (FTN) and Immunotherapy (FZI), Rhine Main Neuroscience Network (rmn2), University Medical Center of the Johannes Gutenberg University Mainz, Mainz, Germany. 8 Institute of Pharmaceutical and Medicinal Chemistry, University of Münster, Münster, Germany. 9 Cellular Electrophysiology and Molecular Biology, Institute for Genetics of Heart Diseases (IfGH), University of Münster, Münster, Germany. 10 Institute of Neuropathology, University of Münster, Münster, Germany. 11 Department of Neurology, Philipps-University, Marburg, Germany. 12 Laboratory of Neurobiology, University of Helsinki, Helsinki, Finland. 13 Molecular Electrophysiology, Institute of Physiology and Center of Mental Health, University of Würzburg, Würzburg, Germany. 14 Institute of Immunology, University of Münster, Münster, Germany. 15 Institute for Medical Biometry and Bioinformatics, Medical Faculty, Heinrich Heine University, Düsseldorf, Germany. 16 Department of Experimental Immunology, Helmholtz Centre for Infection Research, Braunschweig, Germany. 17 Institute for Physiology I, University of Münster, Münster, Germany. 18 Institute of Immunology, Focus Program Immunotherapy (FZI), University Medical Center of the Johannes Gutenberg University Mainz, Mainz, Germany. # Contributed equally.

Inhibition of PCSK9 potentiates immune checkpoint therapy for cancer

Liu X, et al.
November 2021
Authors and Affiliates
Xinjian Liu #,1,2, Xuhui Bao #,1, Mengjie Hu 1, Hanman Chang 1, Meng Jiao 1, Jin Cheng 3, Liyi Xie 4, Qian Huang 3, Fang Li 1, Chuan-Yuan Li 5,6,7; 1 Department of Dermatology, Duke University Medical Center, Durham, NC, USA. 2 Department of Biochemistry, Molecular Cancer Research Center, School of Medicine, Sun Yat-sen University, Shenzhen, Guangdong, China. 3 Molecular Diagnostic Laboratory of Cancer Center, Shanghai General Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China. 4 Department of Radiation Oncology, Fudan University Shanghai Cancer Center, Shanghai, China. 5 Department of Dermatology, Duke University Medical Center, Durham, NC, USA. Chuan.Li@duke.edu. 6 Department of Pharmacology and Cancer Biology, Duke University Medical Center, Durham, NC, USA. Chuan.Li@duke.edu. 7 Duke Cancer Institute, Duke University Medical Center, Durham, NC, USA. Chuan.Li@duke.edu. # Contributed equally.

Response and recurrence correlates in individuals treated with neoadjuvant anti-PD-1 therapy for resectable oral cavity squamous cell carcinoma

Lie S, et al.
November 2021
Authors and Affiliates
Sixue Liu,1,14 Hannah M. Knochelmann,2,3,14 Shirley H. Lomeli,1 Aayoung Hong,1 Mary Richardson,4 Zhentao Yang,1 Raymond J. Lim,5,6 Yan Wang,1 Camelia Dumitras,5 Kostyantyn Krysan,5,7 Cynthia Timmers,8 Martin J. Romeo,9 Carsten Krieg,10 Elizabeth C. O’Quinn,9 Joshua D. Horton,12 Steve M. Dubinett,5,6,7 Chrystal M. Paulos,3,11,15 David M. Neskey,9,12,13,15 and Roger S. Lo1,6,7,15,16,*; 1 Division of Dermatology, Department of Medicine, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA 90095, USA 2 Department of Microbiology and Immunology, Medical University of South Carolina, Charleston, SC 29425, USA 3 Division of Surgical Oncology, Department of Surgery, Winship Cancer Institute, Emory University School of Medicine, Atlanta, GA 30322, USA 4 Department of Pathology, Medical University of South Carolina, Charleston, SC 29425, USA 5 Division of Pulmonary, Critical Care and Sleep Medicine, Department of Medicine, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA 90095, USA 6 Department of Molecular and Medical Pharmacology, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA 90095, USA 7 Jonsson Comprehensive Cancer Center, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA 90095, USA 8 Incyte Pharmaceuticals, Wilmington, DE 19803, USA 9 Hollings Cancer Center, Medical University of South Carolina, Charleston, SC 29425, USA 10 Department of Immunology and Microbiology, Medical University of South Carolina, Charleston, SC 29425, USA 11 Department of Microbiology and Immunology, Emory University, Atlanta, GA 30322, USA 12 Department of Otolaryngology – Head and Neck Surgery, Medical University of South Carolina, Charleston, SC 29425, USA 13Department of Cell and Molecular Pharmacology and Experimental Therapeutics, Medical University of South Carolina, Charleston, SC 29425, USA 14 These authors contributed equally 15 Senior author 16 Lead contact * Correspondence: rlo@mednet.ucla.edu

Minimal Residual Disease Dynamics after Venetoclax-Obinutuzumab Treatment: Extended Off-Treatment Follow-up From the Randomized CLL14 Study.

Al-Sawaf O, et al.
Journal of Clinical Oncology
November 2021
Authors and Affiliates
Othman Al-Sawaf, MD1,2,3; Can Zhang, PhD1; Tong Lu, PhD4; Michael Z. Liao, PhD4; Anesh Panchal, MSc5; Sandra Robrecht, PhD1; Travers Ching, PhD6; Maneesh Tandon, MBChB5; Anna-Maria Fink, MD1; Eugen Tausch, MD7; Christof Schneider, MD7; Matthias Ritgen, MD8; Sebastian Bottcher, MD ¨ 9; Karl-Anton Kreuzer, MD1; Brenda Chyla, PhD10; Dale Miles, PhD4; Clemens-Martin Wendtner, MD11; Barbara Eichhorst, MD1; Stephan Stilgenbauer, MD7,12; Yanwen Jiang, PhD4; Michael Hallek, MD1; and Kirsten Fischer, MD1 1University of Cologne, Faculty of Medicine and University Hospital Cologne, Department I of Internal Medicine, German CLL Study Group, Center for Integrated Oncology Aachen Bonn Cologne Dusseldorf, Germany 2The Francis Crick Institute, London, United Kingdom 3UCL Cancer Institute, University College London, London, United Kingdom 4Genentech, San Francisco, CA 5Roche Products Ltd, Welwyn Garden City, United Kingdom 6Adaptive Biotechnologies Corp, Seattle, WA 7 Department of Internal Medicine III, Ulm University, Ulm, Germany 8Department II of Internal Medicine, University of Schleswig- Holstein, Kiel, Germany 9Clinic III, Special Hematology Laboratory, Rostock University Medical School, Rostock, Germany 10AbbVie Inc, Chicago, IL 11Department of Hematology, Oncology, Immunology, Palliative Care, Infectious Diseases and Tropical Medicine, Munich Clinic Schwabing, Munich, Germany 12Department of Internal Medicine I, Saarland University Medical Center, Homburg, Germany